We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+4.15%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$12.2B
AUM Growth
+$1.52B
(+14%)
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
9.66%
Top 10 Holdings %
Top 10 Hldgs %
19.97%
Holding
2,123
New
434
Increased
455
Reduced
367
Closed
827
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$197M |
| 2 |
Alibaba
BABA
|
+$190M |
| 3 |
Amazon
AMZN
|
+$161M |
| 4 |
GoDaddy
GDDY
|
+$135M |
| 5 |
Walt Disney
DIS
|
+$132M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 2 |
Zoetis
ZTS
|
+$96.3M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$69.5M |
| 4 |
Cadence Design Systems
CDNS
|
+$64.2M |
| 5 |
ANSS
Ansys
ANSS
|
+$60.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.88% |
| 2 | Consumer Discretionary | 23.99% |
| 3 | Technology | 11.1% |
| 4 | Financials | 8.14% |
| 5 | Industrials | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
National Vision
EYE
$1.75B
| $7.89M | 0.06% |
256,694
+239,449
| +1,389% | +$6.86M |
|
352
Ally Financial
ALLY
$13.4B
| $7.87M | 0.06% |
254,036
+100,422
| +65% | +$2.96M |
|
|
FISV
353
Fiserv Inc
FISV
$28.9B
| $7.77M | 0.06% |
85,265
-34,098
| -29% | -$2.99M |
|
354
Central Garden & Pet Co Class A
CENTA
$2.44B
| $7.72M | 0.06% |
391,543
-43,231
| -10% | -$869K |
|
355
T. Rowe Price
TROW
$26.1B
| $7.68M | 0.06% |
70,028
+37,068
| +112% | +$3.9M |
|
356
PUT
iShares MSCI Brazil ETF
EWZ
$9.13B
| $7.63M | 0.06% |
+175,600
| New | +$7.25M |
|
357
Comcast
CMCSA
$85.8B
| $7.61M | 0.06% |
180,032
+125,503
| +230% | +$5.29M |
|
|
ATVI
358
DELISTED
Activision Blizzard
ATVI
| $7.6M | 0.06% |
161,043
-75,063
| -32% | -$3.45M |
|
359
ICF International
ICFI
$1.51B
| $7.58M | 0.06% |
104,159
+73,574
| +241% | +$5.51M |
|
360
AbbVie
ABBV
$465B
| $7.56M | 0.06% |
103,972
+74,484
| +253% | +$5.85M |
|
|
ARRY
361
DELISTED
Array Biopharma Inc
ARRY
| $7.54M | 0.06% |
162,861
+42,116
| +35% | +$1.18M |
|
362
GrafTech
EAF
$200M
| $7.52M | 0.06% |
65,401
+3,948
| +6% | +$463K |
|
363
Greif
GEF
$4.74B
| $7.5M | 0.06% |
230,435
-304,233
| -57% | -$11.3M |
|
364
Live Nation Entertainment
LYV
$42.1B
| $7.5M | 0.06% |
113,186
| – | – |
|
365
QuinStreet
QNST
$916M
| $7.49M | 0.06% |
472,279
-168,480
| -26% | -$2.51M |
|
366
Avanos Medical
AVNS
| $7.46M | 0.06% |
171,064
+126,969
| +288% | +$5.43M |
|
367
Trex
TREX
$4.57B
| $7.46M | 0.06% |
207,942
+107,414
| +107% | +$3.64M |
|
|
CCH.U
368
DELISTED
Collier Creek Holdings Units, each consisting of one Class A ordinary share, $0.0001 par value, and
CCH.U
| $7.42M | 0.06% |
700,000
| – | – |
|
|
GSAH.U
369
DELISTED
GS Acquisition Holdings Corp. Units, each consisting of one share of Class A common stock and one-th
GSAH.U
| $7.41M | 0.06% |
705,860
| – | – |
|
|
CISN
370
DELISTED
Cision Ltd. Ordinary Share
CISN
| $7.4M | 0.06% |
631,218
+588,974
| +1,394% | +$6.98M |
|
371
Illumina
ILMN
$29.2B
| $7.39M | 0.06% |
20,642
+18,961
| +1,128% | +$5.99M |
|
|
TPH
372
DELISTED
Tri Pointe Homes
TPH
| $7.36M | 0.06% |
614,737
+600,514
| +4,222% | +$7.82M |
|
|
GMHIU
373
DELISTED
Gores Metropoulos, Inc. Unit
GMHIU
| $7.33M | 0.06% |
700,000
| – | – |
|
|
PPL
374
PPL Corp
PPL
$27.3B
| $7.24M | 0.06% |
233,515
+233,459
| +416,891% | +$7.24M |
|
375
Merit Medical Systems
MMSI
$4.67B
| $7.2M | 0.06% |
120,796
-33,704
| -22% | -$1.93M |
|
Similar funds
Marshall Wace's Q2 2019 Portfolio in Review
As of Q2 2019, Marshall Wace held 2,123 positions worth $12.2B, up 14% from $10.6B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace deployed $1.17B of net new capital in Q2 2019, opening 434 new positions and adding to 455 existing holdings. Its largest new stake was EPAM Systems: 482,974 shares worth $83.6M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $122M trimmed.
- Marshall Wace's largest Q2 2019 buy was EPAM Systems: 482,974 shares worth $83.6M.
- Marshall Wace added most to Boston Scientific in Q2 2019, an estimated $197M increase.
- Marshall Wace's biggest Q2 2019 reduction was Alphabet (Google) Class A, cutting an estimated $122M.
- Marshall Wace fully exited iShares MSCI Emerging Markets ETF in Q2 2019, selling an estimated $69.5M.
- Marshall Wace's ten largest holdings make up 20% of its $12.2B portfolio in Q2 2019.
- Marshall Wace opened 434 new positions and closed 827 in Q2 2019.
- Marshall Wace's portfolio value rose 14% quarter-over-quarter to $12.2B.
Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.